Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Long, Gráinne H.
Tatro, Amanda R.
Oh, Young S.
Reddy, Sheila R.
Ananthakrishnan, Ashwin N.
Funding for this research was provided by:
This study was supported by Genentech, Inc., a Member of the Roche Group
Text and Data Mining valid from 2019-09-27
12 April 2019
27 September 2019